Revenue Breakdown
Composition ()
No data
Revenue Streams
Medtronic PLC (MDT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cardiac Rhythm & Heart Failure, accounting for 20.0% of total sales, equivalent to $1.71B. Other significant revenue streams include Surgical & Endoscopy and Cranial & Spinal Technologies. Understanding this composition is critical for investors evaluating how MDT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Medtronic PLC maintains a gross margin of 59.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.25%, while the net margin is 12.75%. These profitability ratios, combined with a Return on Equity (ROE) of 9.38%, provide a clear picture of how effectively MDT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MDT competes directly with industry leaders such as BSX and SYK. With a market capitalization of $125.38B, it holds a significant position in the sector. When comparing efficiency, MDT's gross margin of 59.93% stands against BSX's 65.38% and SYK's 62.61%. Such benchmarking helps identify whether Medtronic PLC is trading at a premium or discount relative to its financial performance.
